加入澳门第一赌城在线娱乐
如果你相信科学的力量, join us in our endeavour to push the boundaries of science to deliver life-changing medicines.
抗体药物偶联物:
运送下一波药物
运送下一波药物
什么是抗体药物偶联物?
Antibody drug conjugates (ADCs) are targeted medicines that aim to deliver chemotherapy agents directly to cancer cells via a linker attached to monoclonal antibody. Here we explain their mechanism of action and potential for novel cancer treatments.
adc是如何工作的?
adc结合单克隆抗体(mAb), which binds to a specific target protein on the surface of cancer cells, 用药物, 典型的细胞毒性化疗药物, 通过化学连接.1 与蛋白靶结合后, the ADC is internalised into the cancer cell where it releases the cytotoxic drug. 与传统的化疗不同， adc旨在将药物直接输送到癌细胞中 并尽量减少对健康动物的伤害.1
“完全人类”单克隆抗体, which have been engineered to contain protein sequences encoded by human immunoglobulin genes, 是adc的理想交付平台吗. 它们被设计成具有高度针对性和细胞特异性, 循环半衰期长，免疫原性低.1 They bind to specific cell surface antigens, such as those present on cancer cells.
The chemical ‘linkers’ that join together the antibodies and cytotoxic drugs are highly stable to prevent cleaving (splitting) before the ADC enters the tumour. 与细胞表面的靶蛋白结合后, the ADC is internalised into the cancer cell where it releases the cytotoxic drug.1
The anticancer drugs (or ‘payloads’) have an ability to cause cell death through a variety of mechanisms.1
Learn more about antibody drug conjugate therapies’ mechanism of action:
这些生物活性药物的三个组成部分, 单克隆抗体, 连接剂和细胞毒剂, 所有这些都在确定ADC的治疗潜力方面发挥了作用.
The tumour targeting antibody must be precise to recognise the target cell, so that the receptor on the cell surface can mediate the internalisation of the antibody drug conjugate. The stability of the linker plays an important role in ensuring that linkers are only cleaved inside the tumour cell, and the cytotoxic payload needs to be of the right potency to exert its cancer therapy effect.1
在澳门在线赌城娱乐, we are leveraging our expertise in protein engineering and drug discovery to optimise all aspects of an ADC’s mechanism of action, while using AI powered screening methods to identify clinically relevant targets, which help us match and design each ADC with the biology and sensitivities of specific tumour types.
Our aim is for our ADC portfolio to offer treatment options in a wide range of solid and haematological malignancies. 为了实现这个目标, 继续优化目标选择至关重要, 确定新的有效载荷, focus on developing new linkers and strive to overcome drug resistance.
Learn more about how antibody drug conjugates aim to cause targeted cancer cell death in this video [1:00]:
Chemotherapy is the cornerstone of cancer treatment because it is able to target all vulnerable cells. 肿瘤学研究中心&D our aim is to replace traditional chemotherapy by developing potent and precise ADCs, which have the potential to kill tumour cells by targeting them directly, 同时保留正常细胞.
The technological advancements in developing ADCs are building our confidence in their potential to become the backbone of cancer care. We have limitless possibilities in exploring ADCs as a monotherapy and in combinations with other cancer medicines with potential to bring benefit to a broad population of cancer patients.
Cancer cell targeting: Establishing a portfolio of differentiated ADCs
adc是澳门第一赌城在线娱乐肿瘤学研究的关键部分&D战略. Our vision is for ADCs to replace chemotherapy and become the backbone for novel cancer combination regimens.
Even within one tumour, cancer tissues – and their cell surfaces – vary greatly. There is recognised need for monoclonal antibodies designed for a wide range of tumour specificity, so that cancer therapies can effectively recognise and target all types of cancer cells, 同时保留健康细胞.
澳门第一赌城在线娱乐正在拓展传统单药adc之外的领域, 哪一种针对肿瘤细胞的单一蛋白质, with our multispecific discovery platform capable of targeting two or more target proteins expressed on tumour cells. 多特异性adc是高度靶向性的治疗方法, that have the potential to improve target selectivity and reduce treatment side effects.1
利用澳门第一赌城在线娱乐内部的ADC专业知识, we are demonstrating the strength of our proprietary platform across several ADCs currently in clinical development. 除此之外, we are also working jointly with several external partners to bring ADCs to patients as quickly as possible and augment our clinical pipeline.
与澳门第一赌城在线娱乐合作
澳门第一赌城在线娱乐知道，无论澳门第一赌城在线娱乐的科学多么创新, 无论澳门第一赌城在线娱乐的药物和递送多么有效, 实现澳门第一赌城在线娱乐想要实现的一切, 澳门第一赌城在线娱乐不能单独完成.
参考:
1. 彼得斯C，布朗S. 抗体-药物偶联物作为新型抗癌化疗药物. Biosci代表. 2015;35(4):e00225. 2015年7月14日出版. 可以在: http://onlinelibrary.wiley.com/doi/10.1016/j.febslet.2013.10.015/full. 2024年7月发布.
Veeva ID: Z4-66974
筹备日期:2024年7月